Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Oil stocks lift FTSE 100; China concerns persist

Tue, 22nd Nov 2022 09:07

(Alliance News) - London's FTSE 100 index was outperforming on Tuesday morning as a rising Brent price lifted its heavyweight oil stocks, while other equities were shaken by further Covid measures in China.

The FTSE 100 index was up 47.42 points, 0.6%, at 7,424.27. The FTSE 250 was down 41.14 points, 0.2%, at 19,372.21, and the AIM All-Share was down 0.93 of a point, 0.1%, at 836.66.

The Cboe UK 100 was up 0.6% at 742.63. The Cboe UK 250 was marginally lower at 16,684.68, but the Cboe Small Companies was up 0.3% at 12,958.60.

UK government borrowing struck GBP13.5 billion in October as it booked the first costs of the energy support schemes for households.

Chancellor Jeremy Hunt warned there is "no easy path to balancing the nation's books" after the scale of increased spending was unveiled.

The Office for National Statistics said the reading was GBP4.4 billion higher than the same month last year and was the fourth highest figure for October on record.

The figure for October was, nevertheless, below the expectations of economists, with a consensus of experts predicting borrowing of GBP21 billion for the month.

The pound was quoted at USD1.1845 at the London equities open on Tuesday, up from USD1.1794 at the equities close on Monday. The euro stood at USD1.0262, up from USD1.0236. Against the yen, the dollar was trading at JPY141.82, down from JPY141.96.

Saudi Arabia on Monday denied a report that oil producers were discussing a production increase for their next meeting, saying a cut approved last month would stay in place until the end of 2023.

The Wall Street Journal reported earlier on Monday that Saudi Arabia, which co-leads the OPEC+ cartel along with Russia, and other members were considering an "increase of up to 500,000 barrels a day". 

But the official Saudi Press Agency said on Monday night that energy minister Prince Abdulaziz bin Salman "categorically denies" the report. "It is well known, and no secret, that OPEC+ does not discuss any decisions ahead of its meetings," SPA quoted Prince Abdulaziz as saying. 

Oil prices firmed following the denial, with Brent oil spiking to USD88.27 a barrel early Tuesday from USD83.07 at the London equities close on Monday. The rising price lifted oil majors in the FTSE 100, with BP up 4.3%, Harbour Energy up 4.8%, and Shell rising 2.8%.

"The fear of another round of Covid lockdowns, and the broad-based recession pricing shall continue playing against oil bulls. Still, bulls see two positive factors. First, the US will stop selling its strategic petroleum reserves. And second, the EU sanctions against Russian oil will become effective in December. Both, should support another leg higher in oil," considered Swissquote Bank's Ipek Ozkardeskaya.

Meanwhile, broader stock market sentiment was tested by recession concerns as Covid curbs in China escalate.

Anti-virus controls that are confining millions of Chinese families to their homes and closing shops and offices are spurring fears of further damage to already weak global business and trade.

The ruling Communist Party promised on November 11 to reduce disruption from its "zero-Covid" strategy by making controls more flexible, but the latest wave of outbreaks is challenging that, prompting major cities including Beijing to close off populous districts, shut stores and offices and order factories to isolate their workforces from outside contact.

On Tuesday, the government reported that 28,127 cases were found over the past 24 hours in areas throughout China, including 25,902 with no symptoms. New cases in Beijing have also jumped in recent days, more than doubling from 621 on Sunday to Tuesday's 1,438 – a pandemic record for the city.

In European equities on Tuesday, the CAC 40 in Paris was up 0.1%, while the DAX 40 in Frankfurt was marginally lower.

In China, the Shanghai Composite edged up 0.1%, while the Hang Seng in Hong Kong closed down 1.3%. In Asia on Tuesday, the Japanese Nikkei 225 index closed up 0.6%. The S&P/ASX 200 in Sydney also added 0.6%.

In London, miners made gains early Tuesday, with Glencore up 2.7%, Rio Tinto up 1.8%, and Anglo American up 1.4%.

Gold was quoted at USD1,743.51 an ounce, up sharply from USD1,733.19.

Copper miner Fresnillo added 1.5% in early trade, as it reported progress in electrifying its Juanicipio project.

The miner said that the additional testing requested by Comision Federal de Electricidad, the Chilean state-owned power company, was successful at Juanicipio.

It confirmed the main substation which will provide power to the project passed inspection, and is now approved for use. The main transformer is now energised, and tests in preparation for the final tie-in to the national grid are progressing in line with requirements from CFE.

Fresnillo is confident of meeting the requirements of the regulator, and of achieving a "rapid ramp-up" of operations once full load commissioning begins at Juanicipio.

Elsewhere in the FTSE 100, building materials firm CRH fell 1.4%.

In the nine months to September, CRH said sales were up 13% year-on-year to USD24.4 billion, as positive momentum in the second half continued into the third quarter. This was "driven by resilient demand, strong pricing and continued delivery from its integrated solutions strategy".

CRH expects profit before tax to be ahead of 2021's USD3.1 billion, and earnings before interest, tax, depreciation and amortisation to be around USD5.5 billion, compared to USD5.0 billion in 2021.

GSK rose 0.8%. The pharmaceutical company said it has begun the process of withdrawing its US marketing authorisation application for its blood cancer drug Blenrep, following a request from the US Food & Drug Administration.

Blenrep, or belantamab mafodotin, is an antibody drug conjugate designed to treat adult patients with relapsed or refractory multiple myeloma.

"This request was based on the previously announced outcome of the Dreamm-3 phase III confirmatory trial, which did not meet the requirements of the US FDA Accelerated Approval regulations," GSK explained.

GSK said it will continue the Dreamm clinical program and work with the FDA "on a path forward" for the treatment.

"Dreamm-3 failing to meet its primary endpoint and with this now resulting in a withdrawal will likely compound low sentiment for the drug and GSKs capabilities in oncology," Shore Capital analysts said.

In the FTSE 250, Babcock rose 2.3%.

It said revenue in the six months that ended September 30 rose to GBP2.14 billion from a restated figure of GBP2.13 billion last year. Pretax profit fell to GBP51.2 million, down from a restated figure of GBP58.8 million.

The aerospace and defence firm said the profit decline was due to disposals, and non-cash mark-to-market movement on currency derivative contracts, which offset the positive impacts of the NSM acquisition, and the completion of restructuring in the prior period.

Babcock declared no dividend in relation to the period.

"We expect to see continued operational progress from our focus on execution and growth. We are maintaining our overall financial expectations for the current year," Babcock said.

Shares in online electrical appliance retailer AO World jumped 13%.

AO World guided towards annual adjusted Ebitda at the top end of its GBP20 million to GBP30 million range. This comes despite its pretax loss widening to GBP12 million in the six months that ended September 30 from GBP4 million a year before.

Revenue fell 17% to GBP546 million from GBP661 million.

AO World said its focus on cash and profit has led to "solid progress in a tough environment". It also noted that the cash costs of closing its German business are expected to be "around zero" compared to an original estimate of GBP15 million.

"The swift and decisive actions which the company has taken in shifting its strategy have been recognised by the market, and the shares have enjoyed a rally...over the last three months. However, the more pressing concerns of a deteriorating economic backdrop, consumer retrenchment and a shrinking electricals market remain central to the investment case," observed interactive investor's Richard Hunter.

AO's shares are still down by over 50% in the past year.

Still to come in the economic calendar, there's a eurozone consumer confidence reading at 1600 GMT.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.